{"version":1,"type":"story","url":"https://digestai.news/story/enveda-raises-311-million-series-e-to-advance-nature-derived-ai-drugs","json":"https://digestai.news/story/enveda-raises-311-million-series-e-to-advance-nature-derived-ai-drugs.json","markdown":"https://digestai.news/story/enveda-raises-311-million-series-e-to-advance-nature-derived-ai-drugs.md","slug":"enveda-raises-311-million-series-e-to-advance-nature-derived-ai-drugs","headline":"Enveda raises $311 million Series E to advance nature-derived AI drugs","summary":"Enveda, a biotech startup that applies artificial intelligence to discover medicines from plants and microbes, announced a $311 million Series E financing round. The round was led by Catalio Capital Management with participation from Iconiq and other investors, and values the company at $2 billion, roughly double the valuation it held a year earlier.\n\nFounded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals, Enveda aims to speed up drug discovery by using AI to explore natural product space. While no AI‑discovered drug has yet received FDA approval, Enveda is among the companies moving AI‑identified candidates into human trials. The startup is currently testing several compounds, including one for severe skin conditions and another intended to sustain weight loss after discontinuing GLP‑1 therapies.","keyPoints":["Enveda secured $311 million in a Series E round led by Catalio Capital Management.","The financing values Enveda at $2 billion, double its valuation from a year earlier.","Enveda is testing AI‑discovered drugs for severe skin conditions and post‑GLP‑1 weight‑loss maintenance."],"whyItMatters":"Large funding for AI‑driven natural‑product drug discovery could accelerate novel therapies and signal growing investor confidence in biotech AI approaches.","category":{"slug":"business","name":"Business & Funding","url":"https://digestai.news/category/business"},"entities":{"companies":["Enveda","Catalio Capital Management","Iconiq","Recursion Pharmaceuticals"],"models":[],"people":["Viswa Colluru"]},"firstPublishedAt":"2026-09-23T19:31:28Z","updatedAt":"2026-09-23T19:31:28Z","sourceCount":1,"hasPrimarySource":false,"sources":[{"outlet":"TechCrunch AI","title":"Enveda secures $311M to bring more nature-derived AI drugs into clinical trials","url":"https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials","publishedAt":"2026-09-23T19:31:28Z","type":"press","primary":false,"lead":true}],"sourceNotes":null,"discussions":[],"thread":null,"cite":{"text":"Digest AI, \"Enveda raises $311 million Series E to advance nature-derived AI drugs\", 23 September 2026, https://digestai.news/story/enveda-raises-311-million-series-e-to-advance-nature-derived-ai-drugs","publisher":"Digest AI","title":"Enveda raises $311 million Series E to advance nature-derived AI drugs","datePublished":"2026-09-23T19:31:28Z","url":"https://digestai.news/story/enveda-raises-311-million-series-e-to-advance-nature-derived-ai-drugs"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}